{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-012786","form_type":"8-K","ticker":"ANEB","cik":"0001815974","company_name":"Anebulo Pharmaceuticals, Inc.","filed_at":"2022-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:04:02.448142+00:00","generated_at":"2026-06-25T21:09:51.616547+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Anebulo reports Q3 FY2022 net loss $1.9M; Phase 2 trial fully enrolled","bullets":["Net loss of $1.9M ($0.08/share) for Q3 FY2022 vs $0.6M ($0.68/share) year ago.","Operating expenses rose to $1.9M from $0.6M in prior year period.","Cash and cash equivalents totaled $16.5M as of March 31, 2022.","Completed enrollment of 60 subjects in Part A of Phase 2 trial for ANEB-001; top-line data expected by June 30, 2022.","Company scheduled to present at four investor conferences and a cannabinoid symposium in May-June 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-012786","json":"https://secwatch.observer/filing/0001493152-22-012786.json","markdown":"https://secwatch.observer/filing/0001493152-22-012786.md","text":"https://secwatch.observer/filing/0001493152-22-012786.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1815974/000149315222012786/0001493152-22-012786-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1815974/000149315222012786/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T21:09:51.616547+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}